BioMed

🧬 BioMed Pulse · 2026-09-16 02:01 UTC

BIOMED PULSE

September 16, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in the country, with sustained transmission and no clear slowdown. The overall mood is high alert on multiple simultaneous outbreak fronts, tempered by incremental progress in aging biology and a notable new cancer drug approval.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) - DRC AND UGANDA

As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC has expanded to 61 health zones across six provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo, with one new zone added since the August 28 update. ^[1]
WHO describes this as the largest Ebola outbreak ever reported in the DRC, characterized by sustained transmission in urban and peri-urban settings and expanding faster than any previous Ebola outbreak. ^[2]
As of July 15, 2026, cumulative confirmed cases had already reached 2,124 including 828 deaths, a case fatality rate among confirmed cases above 39 percent. ^[3]
Cross-border transmission to Uganda was confirmed earlier in the outbreak; WHO and CDC have mobilized international responses, with CDC activating enhanced airport screening at Washington-Dulles and Atlanta. ^[4] ^[5] ^[6]

ANDES HANTAVIRUS - M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

As of the fifth WHO Disease Outbreak News report (July 2, 2026), the Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius remains under surveillance, with additional confirmed cases identified since the May 2 notification; initial cluster included two laboratory-confirmed hantavirus cases and five suspected cases among 147 passengers and crew. ^[7] ^[8]
CDC continues active monitoring and response; the agency's June 24 transcript confirms ongoing hantavirus surveillance activity. ^[9]

MEASLES - BANGLADESH

WHO notified of a nationwide measles surge in Bangladesh on April 23, 2026, affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases reported as of that date. ^[10]
This outbreak fits a broader global pattern; global measles cases hit 10.3 million in 2023, and Bangladesh's resurgence underscores gaps in vaccination coverage.

NIPAH VIRUS - INDIA

On June 25, 2026, WHO confirmed one laboratory-confirmed Nipah virus (NiV) infection in an adult male in Kozhikode district, Kerala State, India, who developed neurological symptoms on May 30, 2026.
Kozhikode has a prior history of NiV outbreaks; the case was hospitalized on June 10, 2026, and contact tracing was underway at time of the WHO Disease Outbreak News report.

YELLOW FEVER - GLOBAL

From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission activity in the Americas continued into 2026 following an increase in 2025, according to WHO.

ANIMAL RABIES - UNITED STATES

CDC issued a statement on September 10, 2026 noting increases in recent animal rabies activity and associated human exposures, urging prompt post-exposure prophylaxis.

WEST NILE VIRUS - UNITED STATES

CDC flagged an early and record-pace West Nile virus season as of July 1, 2026, coinciding with America's 250th Independence Day holiday, urging mosquito bite prevention.

CYCLOSPORIASIS - UNITED STATES

Shredded iceberg lettuce served at Taco Bell locations was confirmed as the source of Cyclospora cayetanensis infections in five states, with 1,644 people sick as of July 17, 2026; the outbreak subsequently expanded to four additional states.

DRUG-RESISTANT BACTERIA

A September 23, 2025 CDC report found a dramatic increase in dangerous drug-resistant bacteria in the United States, adding urgency to antimicrobial stewardship efforts.
An extensively drug-resistant Salmonella outbreak linked to moringa powder capsules was reported in February 2026, with three hospitalizations, illustrating the intersection of supplement use and antimicrobial resistance.

🧬 LONGEVITY & AGING

SENESCENCE AND THE SASP

Researchers have characterized the Senescence-Associated Secretory Phenotype (SASP) in both primary skin cells and iPSC-derived skin cells using multiplex assays, offering a standardized toolkit to measure cellular senescence in human tissue models.
A dual antioxidant and epigenetic strategy targeting the self-perpetuating senescence cycle in osteoarthritis joint cells was published in Bioactive Materials, suggesting that breaking the SASP feedback loop may slow cartilage degeneration.

SENOLYTICS IN HIV AND AGING

A Phase II clinical trial (NCT07144293) is testing dasatinib plus quercetin (D+Q) as a senolytic combination in 80 HIV-positive individuals aged 50 or older who are frail or prefrail, measuring improvements in physical function and reduction of senescent cell burden.
Senescent cell clearance is the proposed mechanism; quercetin is a natural flavonoid and dasatinib is an approved tyrosine kinase inhibitor repurposed here to selectively kill senescent cells.

BRAIN AGING AND AMYLOID

An amyloid PET imaging substudy within the Baltimore Longitudinal Study of Aging (NCT07099053) is tracking brain amyloid accumulation over time in cognitively normal adults to identify the earliest biological precursors of cognitive decline.
A separate Europe PMC review in Bioactive Materials catalogued exosome-mediated mechanisms in brain diseases, including Alzheimer's disease, and the potential of engineered young-plasma-derived exosomes to reduce amyloid and tau pathology.

COGNITIVE PROTECTION THROUGH LIPID LOWERING AND TRAINING

A multicenter 2x2 factorial randomized trial (NCT07605130) is evaluating whether digital cognitive training combined with a PCSK9 inhibitor-enhanced lipid-lowering strategy (on top of moderate-intensity statin) can improve cognitive function in patients with intracranial atherosclerotic stenosis, a common cause of stroke and cognitive impairment.

SIRT1, GUT MICROBIOME, AND NEUROCARDIAC AGING

A review in Medical Gas Research connects oxidative stress, SIRT1 deacetylase activity, gut microbiota composition, and metabolic dysfunction as a unified axis underlying cognitive loss and cardiovascular aging, suggesting multi-target interventions are needed.

BONE AND MUSCULOSKELETAL AGING

Loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells was identified as a key driver of impaired fracture healing in aged mice, published in Bioactive Materials.
A dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis was shown to promote repair of age-related bone defects in a preclinical model, representing a novel RNA-medicine approach to skeletal aging.
Quercetin-derived carbon dot nanocomposite hydrogel combining M2 macrophage-derived migrasomes showed regenerative potential in osteoporotic bone defects in Bioactive Materials.

INTERVERTEBRAL DISC DEGENERATION

Engineered senescence-targeting apoptotic extracellular vesicles loaded into injectable hydrogel microspheres mitigated ferroptosis (iron-dependent cell death) in nucleus pulposus cells, a dual mechanism addressing both senescence and oxidative cell death in disc degeneration.
A comprehensive biomaterials review in Bioactive Materials outlined niche reprogramming, precision therapeutics, and structural reconstruction strategies for intervertebral disc regeneration.

ANAESTHESIA AND HIP FRACTURE OUTCOMES IN OLDER ADULTS

A multicenter randomized clinical trial conducted in Germany compared spinal versus general anaesthesia in older patients undergoing hip fracture surgery, with results published in Lancet Healthy Longevity; the authors and an accompanying editorial debated whether anesthetic choice materially changes serious complication rates.

DEPRESCRIBING IN OLDER ADULTS

Two linked commentaries in Lancet Healthy Longevity argued that deprescribing clinical trials must adopt a rationale-first framework before selecting a trial design, addressing the underexplored problem of polypharmacy harms in aging populations.

RADIATION, SENESCENCE, AND HAIR FOLLICLE AGING

Ionizing radiation was shown to induce senescence in dermal papilla cells via inhibition of the FOXM1-KIF20A pathway, providing a mechanistic link between radiation exposure and age-related hair loss, published in Genes and Disease.
Molecular hydrogen was reviewed in Medical Gas Research as a potential protective agent against ionizing radiation-induced cellular damage, acting as a selective antioxidant.

OVARIAN AGING GENETICS

The long-running Genetic Epidemiology of Ovarian Aging study (NCT00501800) continues to enroll participants to identify clinical and genetic markers predicting fertility decline and menopause timing, with environmental factors also assessed.

💊 NEW CURES & APPROVALS

ETCAMAH (CAMIZESTRANT) - ASTRAZENECA

AstraZeneca Pharmaceuticals LP received an original NDA approval (NDA220359) for Etcamah, whose active ingredient is camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) designed to overcome resistance to existing endocrine therapies in breast cancer.

HYRNUO (SEVABERTINIB) - BAYER HEALTHCARE

Bayer Healthcare received a supplemental approval (NDA219972) for Hyrnuo, containing sevabertinib, a targeted kinase inhibitor; the supplement expands the approved use or labeling of this oncology agent.

IBRUTINIB GENERIC - HETERO LABS LTD V

Hetero Labs Ltd V received an original ANDA approval (ANDA211182) for a generic formulation of ibrutinib, the BTK inhibitor used in B-cell malignancies including chronic lymphocytic leukemia and mantle cell lymphoma, broadening patient access.

BRIVARACETAM GENERIC - ZHEJIANG JUTAI PHARM

Zhejiang Jutai Pharm received an original ANDA approval (ANDA220136) for generic brivaracetam, a synaptic vesicle protein SV2A ligand antiseizure medication, adding a new low-cost source for epilepsy treatment.

LACOSAMIDE - REGCON HOLDINGS

Regcon Holdings received a supplemental ANDA approval (ANDA208308) for lacosamide, another antiseizure agent that enhances slow inactivation of voltage-gated sodium channels, used in focal-onset epilepsy.

ISOTRETINOIN GENERIC - AUROBINDO PHARMA

Aurobindo Pharma Ltd received an original ANDA approval (ANDA220336) for generic isotretinoin, a retinoid used in severe nodular acne, increasing generic market supply.

AMELUZ (AMINOLEVULINIC ACID HCL) - BIOFRONTERA

Biofrontera received a supplemental NDA approval (NDA208081) for Ameluz (aminolevulinic acid hydrochloride), a photosensitizer used in photodynamic therapy for actinic keratosis.

TOPIRAMATE GENERIC - MICRO LABS

Micro Labs received an original ANDA approval (ANDA219183) for generic topiramate, an antiseizure and migraine prophylaxis drug.

🧪 CLINICAL TRIALS

SENOLYTIC D+Q IN FRAIL HIV-POSITIVE ADULTS (NCT07144293)

Phase II trial testing dasatinib 100 mg plus quercetin 1,000 mg as a senolytic regimen in 80 participants aged 50 or older with HIV who are frail or prefrail, measuring physical function improvement and safety; enrolling as of September 15, 2026.

PCSK9 INHIBITOR PLUS DIGITAL COGNITIVE TRAINING IN INTRACRANIAL ATHEROSCLEROSIS (NCT07605130)

A 2x2 factorial multicenter randomized trial evaluating PCSK9 inhibitor-enhanced lipid lowering on top of moderate statin therapy, with or without digital cognitive training, in patients with intracranial atherosclerotic stenosis, targeting both stroke prevention and cognitive outcomes.

AMYLOID PET IN BALTIMORE LONGITUDINAL STUDY OF AGING (NCT07099053)

Observational imaging substudy tracking amyloid protein accumulation in cognitively normal aging adults using PET scans, aiming to define preclinical Alzheimer's trajectories within the established Baltimore cohort.

BELUMOSUDIL VERSUS BEST AVAILABLE THERAPY IN CHRONIC GRAFT-VERSUS-HOST DISEASE (NCT07771439)

Participants aged 12 and older with chronic graft-versus-host disease (cGVHD) are randomized 1:1 to belumosudil, a ROCK2 inhibitor, or best available therapy, stratified by NIH 2014 consensus severity criteria (moderate versus severe) and concomitant corticosteroid or calcineurin inhibitor use.

CHILDHOOD ADVERSITY AND ADULT METABOLISM (NCT06690294)

Natural history study examining how unpredictability during childhood affects adult eating behaviors, food consumption patterns, and metabolic outcomes; currently enrolling healthy adults at NIH.

BP-LT FOOD INGREDIENT SAFETY TRIAL (NCT07819695)

Phase I placebo-controlled double-blind trial evaluating safety and tolerability of BP-LT, a stable protein ingredient active in the gastrointestinal tract without systemic absorption, as a dietary supplement; this is Part I of a two-part development program.

OVARIAN AGING GENETICS STUDY (NCT00501800)

Long-running study identifying genetic and environmental markers of ovarian aging and fertility decline; updated activity recorded September 15, 2026.

IL-15 SUPERAGONIST N-803 WITH OR WITHOUT ETBX-071 VACCINE IN RECURRENT PROSTATE CANCER (NCT07686380)

Trial testing IL-15 superagonist N-803 alone or combined with the ETBX-071 vaccine in biochemically recurrent prostate cancer (BCR) after stereotactic body radiation therapy, targeting 30,000 to 50,000 men affected by BCR annually.

📢 PUBLIC HEALTH

LISTERIA OUTBREAK IN PREPARED MEALS - ONGOING

CDC expanded the Listeria monocytogenes outbreak to include additional prepared foods, reporting 3 additional illnesses and 1 additional death as of September 26, 2025; as of October 30, 2025, illnesses continued despite product recalls, and consumers were urged to check refrigerators and freezers.

SALMONELLA IN METABOLIC MEALS HOME DELIVERY FOODS

As of September 5, 2025, 16 people in 10 states were sick from the same Salmonella strain linked to certain Metabolic Meals home delivery food products; investigation ongoing.

CONGENITAL SYPHILIS RISES FOR 12TH CONSECUTIVE YEAR

New CDC data published September 24, 2025 show U.S. cases of newborn syphilis increased for the 12th consecutive year in 2024, underlining persistent gaps in prenatal screening and treatment.

DRUG OVERDOSE DEATHS DECLINING

CDC reported a 27 percent decrease in drug overdose deaths in provisional 2024 data, continuing a trend of nearly 24 percent decline reported in February 2025, marking a significant public health improvement.

KINDERGARTEN VACCINATION RATES

CDC data released August 17, 2026 show kindergarten vaccination rates remain high nationally, with only a 0.1 percent decline in coverage, though measles vaccination gaps continue to drive outbreak risk.

NEW WORLD SCREWWORM RESPONSE

CDC activated its Emergency Operations Center for a New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026, marking an unusual parasitic threat requiring public health coordination.

NOTE: This briefing is informational only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260916-02-v77 · 2026-09-16 02:01 UTC · pulse.uzylab.com

🧬 BioMed Pulse · 2026-09-16 02:01 UTC

⚡ TL;DR

🦠 OUTBREAKS & VIRUSES

🧬 LONGEVITY & AGING

💊 NEW CURES & APPROVALS

🧪 CLINICAL TRIALS

📢 PUBLIC HEALTH

📎 Sources

Read next

BioMed Pulse · 2026-10-04 02:01 UTC

BioMed Pulse · 2026-10-03 02:01 UTC

BioMed Pulse · 2026-10-02 02:01 UTC